Eli Lilly and Company (NYSE:LLY) Shares Down 2.3% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s stock price fell 2.3% on Monday . The company traded as low as $1,071.60 and last traded at $1,079.9610. 2,648,538 shares were traded during mid-day trading, a decline of 17% from the average session volume of 3,202,486 shares. The stock had previously closed at $1,105.00.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly signed new licensing and collaboration deals in Asia, including agreements involving Haisco and Hanmi, reinforcing management’s push to broaden its pipeline and add future growth drivers. Reuters article on Haisco collaboration Hanmi licensing deal article
• Positive Sentiment: Lilly reported strong Phase 3 data for Retevmo, saying the drug cut recurrence or death risk by 83% in early-stage RET fusion-positive lung cancer, which could expand the therapy’s label and boost future sales. PR Newswire Retevmo trial article
• Positive Sentiment: Wall Street commentary remains constructive after CEO David Ricks highlighted the company’s latest growth engine, adding to investor confidence in Lilly’s ability to sustain momentum from its obesity and broader drug portfolio. Motley Fool CEO commentary article
• Positive Sentiment: LLY continues to be viewed as a high-momentum stock, with articles highlighting its “Nvidia-like” growth, strong Q1 results, and continued analyst enthusiasm, all of which can help keep sentiment elevated. Yahoo Finance AI stock pick article
• Neutral Sentiment: Some market coverage noted that Novo Nordisk’s oral Wegovy pill is still outselling Lilly’s competing tablet, though growth in that category is slowing as the market absorbs the new entrant. Proactive Investors GLP-1 competition article

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. CICC Research increased their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Argus increased their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Jefferies Financial Group increased their target price on shares of Eli Lilly and Company from $1,300.00 to $1,330.00 in a research note on Thursday, May 21st. Weiss Ratings lowered shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, May 19th. Finally, Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,227.00.

Eli Lilly and Company Trading Down 2.3%

The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The firm has a market cap of $1.02 trillion, a PE ratio of 38.36, a P/E/G ratio of 1.21 and a beta of 0.53. The company’s 50-day moving average is $955.92 and its 200 day moving average is $1,010.09.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company in the 4th quarter valued at $25,000. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC grew its stake in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares during the last quarter. Basso Capital Management L.P. acquired a new position in Eli Lilly and Company in the 4th quarter valued at $30,000. Finally, 10Elms LLP grew its stake in Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.